Napsin A is an independent prognostic factor in surgically resected adenocarcinoma of the lung

Lung Cancer

Volumn 77, Issue 1, 2012, Pages 156-161

  Lee, Jin Gu ^a   Kim, Sewha ^a   Shim, Hyo Sup ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Adenocarcinoma; Lung; Napsin A; Prognosis; TTF 1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; NAPSIN A; PROTEIN; THYROID TRANSCRIPTION FACTOR 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; FEMALE; HISTOLOGY; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATION; OVERALL SURVIVAL; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ASPARTIC ACID ENDOPEPTIDASES; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84862799074     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.02.013     Document Type: Article

References (38)

1. Travis W.D., Brambilla E., Noguchi M., Nicholson A.G., Geisinger K.R., Yatabe Y., et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285.
2. Aberle D.R., Adams A.M., Berg C.D., Black W.C., Clapp J.D., Fagerstrom R.M., et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365:395-409.
3. Cataldo V.D., Gibbons D.L., Perez-Soler R., Quintas-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011, 364:947-955.
4. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
5. Langer C.J., Besse B., Gualberto A., Brambilla E., Soria J.C. The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:5311-5320.
6. Shim H.S., Lee D.H., Park E.J., Kim S.H. Histopathologic characteristics of lung adenocarcinomas with epidermal growth factor receptor mutations in the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Lung Adenocarcinoma Classification. Arch Pathol Lab Med 2011, 135:1329-1334.
7. Yoshida A., Tsuta K., Nakamura H., Kohno T., Takahashi F., Asamura H., et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 2011, 35:1226-1234.
8. Rekhtman N., Ang D.C., Sima C.S., Travis W.D., Moreira A.L. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 2011, 24:1348-1359.
9. Travis W.D., Rekhtman N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med 2011, 32:22-31.
10. Bishop J.A., Sharma R., Illei P.B., Napsin A. and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol 2010, 41:20-25.
11. Mukhopadhyay S., Katzenstein A.L. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011, 35:15-25.
12. Ye J., Findeis-Hosey J.J., Yang Q., McMahon L.A., Yao J.L., Li F., et al. Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung. Appl Immunohistochem Mol Morphol 2011, 19:313-317.
13. Noh S., Shim H. Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: a tissue microarray study of poorly differentiated areas. Lung Cancer 2011, [e-pub].
14. Tatnell P.J., Powell D.J., Hill J., Smith T.S., Tew D.G., Kay J., Napsins: new human aspartic proteinases. Distinction between two closely related genes. FEBS Lett 1998, 441:43-48.
15. Chuman Y., Bergman A., Ueno T., Saito S., Sakaguchi K., Alaiya A.A., Napsin A., et al. a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas. FEBS Lett 1999, 462:129-134.
16. Brasch F., Ochs M., Kahne T., Guttentag S., Schauer-Vukasinovic V., Derrick M., et al. Involvement of napsin A in the C- and N-terminal processing of surfactant protein B in type-II pneumocytes of the human lung. J Biol Chem 2003, 278:49006-49014.
17. Ueno T., Linder S., Na C.L., Rice W.R., Johansson J., Weaver T.E. Processing of pulmonary surfactant protein B by napsin and cathepsin H. J Biol Chem 2004, 279:16178-16184.
18. Aikawa E., Kawahara A., Hattori S., Yamaguchi T., Abe H., Taira T., et al. Comparison of the expression levels of napsin A, thyroid transcription factor-1, and p63 in nonsmall cell lung cancer using cytocentrifuged bronchial brushings. Cancer Cytopathol 2011, 119:335-345.
19. Boggaram V. Thyroid transcription factor-1 (TTF-1/Nkx2. 1/TITF1) gene regulation in the lung. Clin Sci (Lond) 2009, 116:27-35.
20. Yatabe Y., Mitsudomi T., Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 2002, 26:767-773.
21. Weir B.A., Woo M.S., Getz G., Perner S., Ding L., Beroukhim R., et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007, 450:893-898.
22. Kwei K.A., Kim Y.H., Girard L., Kao J., Pacyna-Gengelbach M., Salari K., et al. Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene 2008, 27:3635-3640.
23. Takahashi T., Yatabe Y., Tanimoto M., Sekido Y., Mitsudomi T., Matsubara H., et al. Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. Cancer Res 2007, 67:6007-6011.
24. Kendall J., Liu Q., Bakleh A., Krasnitz A., Nguyen K.C., Lakshmi B., et al. Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proc Natl Acad Sci USA 2007, 104:16663-16668.
25. Yatabe Y., Kosaka T., Takahashi T., Mitsudomi T. EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. Am J Surg Pathol 2005, 29:633-639.
26. Berghmans T., Paesmans M., Mascaux C., Martin B., Meert A.P., Haller A., et al. Thyroid transcription factor 1 - a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol 2006, 17:1673-1676.
27. Anagnostou V.K., Syrigos K.N., Bepler G., Homer R.J., Rimm D.L. Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol 2009, 27:271-278.
28. Perner S., Wagner P.L., Soltermann A., LaFargue C., Tischler V., Weir B.A., et al. TTF1 expression in non-small cell lung carcinoma: association with TTF1 gene amplification and improved survival. J Pathol 2009, 217:65-72.
29. Winslow M.M., Dayton T.L., Verhaak R.G., Kim-Kiselak C., Snyder E.L., Feldser D.M., et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature 2011, 473:101-104.
30. Hosono Y., Yamaguchi T., Mizutani E., Yanagisawa K., Arima C., Tomida S., et al. MYBPH, a transcriptional target of TTF-1, inhibits ROCK1, and reduces cell motility and metastasis. EMBO J 2011, 31:481-493.
31. Barletta J.A., Perner S., Iafrate A.J., Yeap B.Y., Weir B.A., Johnson L.A., et al. Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med 2009, 13:1977-1986.
32. Li X., Wan L., Shen H., Geng J., Nie J., Wang G., et al. Thyroid transcription factor-1 amplification and expressions in lung adenocarcinoma tissues and pleural effusions predict patient survival and prognosis. J Thorac Oncol 2012, 7:76-84.
33. Turner B.M., Cagle P.T., Sainz I.M., Fukuoka J., Shen S.S., Jagirdar J., Napsin A. a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med 2012, 136:163-171.
34. Mukhopadhyay S. Utility of small biopsies for diagnosis of lung nodules: doing more with less. Mod Pathol 2012, 25:S43-S57.
35. Yatabe Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev 2010, 29:23-36.
36. Liaudet-Coopman E., Beaujouin M., Derocq D., Garcia M., Glondu-Lassis M., Laurent-Matha V., Cathepsin D., et al. newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett 2006, 237:167-179.
37. Ueno T., Elmberger G., Weaver T.E., Toi M., Linder S. The aspartic protease napsin A suppresses tumor growth independent of its catalytic activity. Lab Invest 2008, 88:256-263.
38. Ueno T., Linder S., Elmberger G. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. Br J Cancer 2003, 88:1229-1233.